Breaking News Instant updates and real-time market news.

ZGNX

Zogenix

$35.05

22.175 (172.23%)

, GWPH

GW Pharmaceuticals

$101.49

-10.78 (-9.60%)

16:20
09/29/17
09/29
16:20
09/29/17
16:20

On The Fly: Top stock stories for Friday

Stocks opened little changed, drifted higher in the morning hours, and then settled into a narrow range in the afternoon. The market put the finishing touches on its eighth straight quarter of gains and closed September in positive territory after one of the least volatile monthly performances in a long time. ECONOMIC EVENTS: In the U.S., personal income rose 0.2% in August, with spending up 0.1%. The Chicago PMI surged 6.3 points to 65.2 in September, which was much stronger than expected and represents the second highest reading going back to November 2014. The University of Michigan consumer sentiment reading slid 1.7 points to 95.1 in the final reading for September, down from 96.8 in August and below the 95.3 preliminary September print. In energy news, Baker Hughes reported that the U.S. rig count is up 5 rigs from last week to 940. COMPANY NEWS: Shares of Zogenix (ZGNX) surged 172% to $35.05 after the company said its epilepsy drug met its primary endpoint in a late-stage study. Meanwhile, competitor GW Pharmaceuticals (GWPH), which is at work on a cannabidiol-based epilepsy drug, slid 9.6%... Shares of Tyson Foods (TSN) gained 7.64% after the meat producer raised its earnings guidance, primarily due to "much better than expected" earnings in its Beef segment... Meanwhile, Equifax (EFX) shares were in focus after Bloomberg reported that the company's board of directors has formed a special panel to review the share sales made by executives just days after they found that the company was hacked. MAJOR MOVERS: Among the notable gainers was A10 Networks (ATEN), which jumped 13.43% after raising its Q3 revenue view. Also higher was Finish Line (FINL), which gained 3.17% after Wells Fargo analyst Tom Nikic pegged a takeout range at $14-$16 per share following the New York Post's report that the company is in talks to be bought by Sports Direct. Ionis Pharmaceuticals (IONS) and Sarepta Therapeutics (SRPT) were among the noteworthy losers, dropping 3.63% and 3.8%, respectively, after the new, more user-searchable FDA Adverse Events Reporting System drove attention to reported deaths seen in patients using the companies' therapies. However, a number of analysts argued that the data is being taken out of context and the stock reactions were unwarranted, while the companies themselves also issued statements that the deaths were disease related, not drug related. Also lower was Lousiana-Pacific (LPX), which dropped 5.22% after BMO Capital downgraded the stock to Underperform, citing valuation and upcoming OSB supply increases. INDEXES: The Dow rose 23.89, or 0.11%, to 22,405.09, the Nasdaq gained 42.51, or 0.66%, to 6,495.96, and the S&P 500 advanced 9.30, or 0.37%, to 2,519.36.

ZGNX

Zogenix

$35.05

22.175 (172.23%)

GWPH

GW Pharmaceuticals

$101.49

-10.78 (-9.60%)

TSN

Tyson Foods

$70.45

5 (7.64%)

KBH

KB Home

$24.12

1.9 (8.55%)

EFX

Equifax

$105.99

-0.38 (-0.36%)

ATEN

A10 Networks

$7.56

0.91 (13.68%)

FINL

Finish Line

$12.03

0.37 (3.17%)

IONS

Ionis Pharmaceuticals

$50.70

-1.91 (-3.63%)

SRPT

Sarepta

$45.36

-1.79 (-3.80%)

LPX

Louisiana-Pacific

$27.08

-1.49 (-5.22%)

  • 10

    Oct

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

ZGNX Zogenix
$35.05

22.175 (172.23%)

09/29/17
WBLR
09/29/17
UPGRADE
WBLR
Outperform
William Blair calls Zogenix data best to date in upgrade to Outperform
William Blair analyst Tim Lugo earlier today upgraded Zogenix (ZGNX) to Outperform from Market Perform saying the company's Dravet data is the best to date. Zogenix's ZX008 looks superior to GW Pharmaceuticals' (GWPH) cannabinoid candidate, Epidiolex, Lugo told investors in a research note. Shares of Zogenix are up 179% to $35.88 after the company this morning announced positive top-line results from its first Phase 3 trial for ZX008 for the treatment of Dravet syndrome. GW Pharmaceuticals is down 8% to $102.79 in afternoon trading.
09/29/17
LEER
09/29/17
NO CHANGE
LEER
Outperform
Zogenix Dravet data looks like 'best case scenario,' says Leerink
Leerink analyst Paul Matteis said the top-line results for the ZX008 study in Dravet Syndrome reported by Zogenix look like a "best case scenario" for the company, noting that the magnitude of clinical benefit was not only better than expected but also in the ballpark of prior compassionate use studies that conveyed an "unprecedented level" of benefit. The analyst, who has an Outperform rating on Zogenex, said his model is under review pending the company's call to discuss the data.
09/29/17
STFL
09/29/17
NO CHANGE
Target $55
STFL
Buy
Zogenix price target raised to $55 from $26 at Stifel
Stifel analyst Annabel Samimy said Zogenix reported "unequivocally positive" Phase 3 data for ZX008 in Dravet syndrome with a safety profile consistent with known fenfluramine adverse events and clear of cardiovascular effects. The analyst, who called the results "far better than we expected," reiterates her Buy rating on the stock and raised her price target of Zogenix to $55 from $26.
09/29/17
WBLR
09/29/17
UPGRADE
WBLR
Outperform
Zogenix upgraded to Outperform from Market Perform at William Blair
GWPH GW Pharmaceuticals
$101.49

-10.78 (-9.60%)

08/16/17
EVER
08/16/17
INITIATION
Target $154
EVER
Outperform
GW Pharmaceuticals initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated GW Pharmaceuticals with an Outperform and a $154 price target.
08/08/17
MAXM
08/08/17
DOWNGRADE
MAXM
Hold
GW Pharmaceuticals downgraded to Hold from Buy at Maxim
Maxim analyst Gabrielle Zhou downgraded GW Pharmaceuticals (GWPH) to Hold after rival Zynerba Pharmaceuticals (ZYNE) reported a failed Phase 2 study evaluating a cannabidiol gel in adult epilepsy patients with focal seizures. The selloff yesterday in GW shares suggests investor concern that GW's botanically derived cannabidiol gel's benefit may be "moderate at best," Zhou tells investors in a research note. The analyst now sees a "more neutral" risk/reward for shares of GW.
06/12/17
MAXM
06/12/17
NO CHANGE
Target $32
MAXM
Buy
Zynerba an 'excellent value' compared to GW Pharmaceuticals, says Maxim
Maxim analyst Gabrielle Zhou said she views Zynerba's (ZYNE) product candidates as "de-risked" alternatives to GW Pharmaceuticals' (GWPH) and calls the stock an "excellent value play" compared to GW, citing the facts that ZYN002 has a better safety and bioavailability profile than GW Pharma's Epidiolex. ZYN002 is also synthetic, not plant based, which could lead to higher margins and better quality control, Zhou tells investors. She keeps a Buy rating and $32 price target on Zynerba shares, adding that 2017 could be "transformational" for the company.
TSN Tyson Foods
$70.45

5 (7.64%)

08/08/17
GSCO
08/08/17
NO CHANGE
Target $79
GSCO
Buy
Tyson Foods trading at a discount, says Goldman Sachs
Goldman analyst Adam Samuelson said Tyson's Q3 beat and optimistic 2018 guidance were encouraging following several quarters of lackluster performance in Prepared/Chicken. The analyst has increased confidence in FY18 sustained growth and said Tyson's value-added businesses are not being appropriately reflected in current valuation. Samuelson rates Tyson a Buy with a $79 price target.
08/08/17
FBCO
08/08/17
NO CHANGE
Target $70
FBCO
Neutral
Tyson Foods price target raised to $70 from $65 at Credit Suisse
Credit Suisse analyst Robert Moskow raised his price target for Tyson Foods to $70 from $65 after quarterly results. The analyst reiterates a Neutral rating on the shares.
07/19/17
07/19/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Tyson Foods (TSN) reinstated with a Neutral at Credit Suisse. 2. Bob Evans (BOBE) initiated with a Buy at Berenberg. 3. Quanex (NX) coverage assumed with an Outperform at Wedbush. 4. Agile Therapeutics (AGRX) initiated with a Buy at H.C. Wainwright. 5. Caesars (CZR) re-initiated with an Outperform at Imperial Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/19/17
FBCO
07/19/17
INITIATION
Target $65
FBCO
Neutral
Tyson Foods reinstated with a Neutral at Credit Suisse
Credit Suisse analyst Robert Moskow reinstated Tyson Foods with a Neutral rating and $65 price target following its acquisition of Advance Pierre.
KBH KB Home
$24.12

1.9 (8.55%)

09/29/17
MZHO
09/29/17
UPGRADE
MZHO
Neutral
KB Home upgraded to Neutral from Underperform at Mizuho
Mizuho analyst Haendel St. Juste upgraded KB Home to Neutral with a $21 price target citing fair valuation.
09/22/17
WEDB
09/22/17
NO CHANGE
Target $26
WEDB
Outperform
KB Home forward estimates may be at risk due to storms, says Wedbush
Wedbush analyst Jay McCanless says he expects KB Home to report Q3 earnings per share of 50c, above the consensus estimate of 46c. Since Hurricane Harvey struck near the end of the company's Q3 and Hurricane Irma struck after the quarter ended, most of KB's closings and orders in the affected areas occurred before the storms hit, McCanless tells investors in a pre-earnings research note. The analyst is comfortable being above consensus for Q3 but thinks his forward earnings estimates may be at risk from storm-related issues. He reiterates an Outperform rating on KB Home with a $26 price target.
07/10/17
MZHO
07/10/17
DOWNGRADE
MZHO
Underperform
KB Home downgraded to Underperform from Neutral at Mizuho
07/11/17
LEHM
07/11/17
DOWNGRADE
Target $37
LEHM
Toll Brothers downgraded to Underweight from Equal Weight at Barclays
As previously reported, Barclays analyst Michael Dahl downgraded Toll Brothers (TOL) to Underweight and keeps a $37 price target for the shares. The analyst says his firm's June agency survey indicated moderating buyer traffic trends. He sees risk that near-term catalysts for builders will disappoint relative to rising expectations. As such, Dahl recommends "tactically" reducing exposure to homebuilder stocks. Along with Toll Brothers, the analyst this morning downgraded TRI Pointe (TPH), PulteGroup (PHM) and Lennar (LEN) to Equal Weight. He also upgraded CalAtlantic (CAA) to Equal Weight. Dahl reiterates Underweight ratings on KB Home (KBH), Meritage Homes (MTH) and Realogy (RLGY).
EFX Equifax
$105.99

-0.38 (-0.36%)

09/22/17
WELS
09/22/17
UPGRADE
Target $127
WELS
Outperform
Equifax upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst William Warmington upgraded Equifax to Outperform following the 31% decline in the shares since the security breach was announced on September 7. The magnitude of the breach has created an "attractive entry point for this high-quality consumer credit franchise," Warmington tells investors in a research note. Despite the negative press, the analyst believes Equifax's core business-to-business segment will be largely unaffected from the breach. He lowered his price target for the shares to $127 from $135. Equifax closed yesterday up $2.25 to $98.25 and is trading up in the premarket another $2.45 to $100.70.
09/18/17
OPCO
09/18/17
NO CHANGE
Target $45
OPCO
Outperform
Equifax breach could become tailwind for Fortinet, says Oppenheimer
Following a meeting with Fortinet's (FTNT) management, Oppenheimer analyst Shaul Eyal believes the Equifax (EFX) breach could yield an effect akin to the late-2013 Target (TGT) breach, whereby heightened security awareness and an increase in involvement across boards and C-level executives which could convert into increased security budgets. Further, the analyst believes Fortinet is focused on better positioning itself for IT trends, and that its "strong growth" in subscription services remains in-tact and higher-end appliance traction remains a strong-point for its product segment. Eyal reiterates an Outperform rating and $45 price target on Fortinet's shares.
09/29/17
WBLR
09/29/17
NO CHANGE
WBLR
Outperform
William Blair, despite estimate cuts, positive on Equifax risk/reward
William Blair analyst Timothy McHugh lowered his estimates for Equifax to account for the data breach. The analyst cut his 2017 earnings per share estimate by 23c to $5.83, 2018 estimate by 83c to $5.91, and 2019 estimate by $1.05 to $6.35. Equifax will exclude some of the short-term items directly associated with the breach from its adjusted earnings, so the estimates do not include those items, McHugh tells investors in a research note. He now assumes organic growth for Equifax of 2% in 2018 and 6% in 2019. The analyst, while admitting the stock's multiple will not return to historical levels "anytime soon," views the company's risk/reward profile as "positive at current levels, particularly for patient investors." He keeps an Outperform rating on Equifax.
09/19/17
DBAB
09/19/17
NO CHANGE
Target $115
DBAB
Buy
Deutsche sees breach costing Equifax 'well below' $1B, calls selloff 'excessive'
Deutsche Bank analyst Kevin McVeigh lowered his price target for Equifax to $115 from $160 saying the shares could volatile around the congressional hearings on October 3. The analyst, however, views the $6.5B, or 35%, equity loss in a week as "excessive." He sees an $85 to $145 52-week trading range for the shares. Equifax closed yesterday up $1.40 to $94.38. Inflection in sentiment typically occurs 60-90 days post a congressional hearing before trading higher, McVeigh tells investors in a research note titled "Charting unchartered territory." He believes the total impact of the breach, not adjusting for insurance or other offsets, should be "well below" $1B. The analyst keeps a Buy rating on Equifax shares.
ATEN A10 Networks
$7.56

0.91 (13.68%)

07/14/17
07/14/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Market Perform from Outperform at Cowen with analyst John Blackledge lowering his 2017 and longer-term advertising revenue estimates for Snap to reflect a more competitive environment within Digital advertising. He also believes contribution from the company's new advertising monetization products like Direct Response and Self Serve are not likely to be meaningful in the near term. 2. CyberArk (CYBR) was downgraded to Equal Weight from Overweight at Stephens, to Hold from Buy at Deutsche Bank, and to Neutral from Overweight at JPMorgan. 3. At Home Group (HOME) downgraded to Neutral from Buy at Goldman Sachs with analyst Matthew Fassler citing valuation with the shares up 82% since his upgrade to Buy on November 30, 2016. 4. A10 Networks (ATEN) downgraded to Sector Weight from Overweight at KeyBanc with analyst Alex Kurtz citing "substantially" lower projected growth rates following the company's weaker than expected preliminary second quarter results. 5. Himax (HIMX) downgraded to Underperform from Perform at Oppenheimer with analyst Andrew Uerkwitz saying lowered smartphone expectations in China for 2017 will weigh on the company's near-term orders. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/14/17
KEYB
07/14/17
DOWNGRADE
KEYB
Sector Weight
A10 Networks downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Alex Kurtz downgraded A10 Networks to Sector Weight citing "substantially" lower projected growth rates following the company's weaker than expected preliminary Q2 results. The analyst believes regaining demand momentum could take several quarters.
07/14/17
PIPR
07/14/17
DOWNGRADE
Target $136
PIPR
Neutral
F5 Networks downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Troy Jensen downgraded F5 Networks (FFIV) to Neutral and lowered his price target for the shares to $136 from $144. The product refresh cycle is not playing out as expected and product growth "could remain challenged," Jensen tells investors in a research note. His firm's Q2 channel survey highlighted a quarter-over-quarter downtick in demand for F5 with below plan responses outnumbering above plan responses, reversing a three quarter uptrend. Jensen says the negative preannouncement from A10 Networks (ATEN) only compounded his concerns. The analyst believes F5's previous growth assumptions and forward earnings are at risk.
10/31/16
DADA
10/31/16
UPGRADE
DADA
Buy
A10 Networks upgraded on valuation at DA Davidson
As noted earlier, DA Davidson upgraded A10 Networks to Buy from Neutral. Analyst Mark Kelleher upgraded the stock based on valuation. He says that the company "remains well-positioned in its core ADC and DDoS markets" despite its September quarter revenue miss. Target $10.50.
FINL Finish Line
$12.03

0.37 (3.17%)

09/19/17
JEFF
09/19/17
NO CHANGE
JEFF
Jefferies cuts Nike target, says share loss to adidas accelerating
Survey work shows Nike (NKE) is ceding market share to adidas (ADDYY) in both Europe and the U.S. at an accelerating pace, especially in running, Jefferies analyst Randal Konik tells investors in a research note. The analyst's webscrape analysis shows Nike has 35 shoes in the top 60 sellers versus 52 last year, while adidas has risen to 24 styles, versus just 2 last year. Konik expects downward estimate revisions and multiple compression for Nike. He lowered his estimates for the company and cut his price target for the shares to $49 from $60. The shoemaker closed yesterday down 37c to $53.50. The analyst reiterates a Hold rating on the name. Konik also views Nike's eroding market share as negative for both Foot Locker (FL) and Finish Line (FINL).
09/19/17
WELS
09/19/17
DOWNGRADE
Target $13
WELS
Underperform
Under Armour downgraded to Underperform from Market Perform at Wells Fargo
Wells Fargo analyst Tom Nikic downgraded Under Armour (UAA) to Underperform and cut his price target for the shares to $13 from $17. With consumers having filled their closets with athletic wear over the past seven years, the category "appears poised to take a breather for now," Nikic tells investors in a research note. The analyst believes the trend change away from performance has left Under Armour "offsides" from a fashion perspective. Further, he notes that unlike Nike (NKE), Under Armour still generates most of its revenue in North America, where the athletic space is seeing much more pressure. The stock's valuation "still appears quite lofty," Nikic argues. The analyst lowered his estimates for Nike, Under Armour, lululemon (LULU) and Finish Line (FINL), but downgraded only Under Armour.
09/29/17
WELS
09/29/17
NO CHANGE
Target $12
WELS
Market Perform
Finish Line takeout could be in $14-$16 per share range, says Wells Fargo
Wells Fargo analyst Tom Nikic pegs Finish Line's takeout range at $14-$16 per share after the New York Post reported that the company is in talks to sell itself to U.K.- based retailer Sports Direct. Finish Line closed yesterday up 41c, or 4%, to $11.66. A potential deal could result in "significant upside" to Finish Line shares, Nikic tells investors in a research note. He believes a deal could make sense from Sports Direct's perspective and raised his price target for Finish Line shares to $12 from $9. The new price target assumes a 50% probability that a deal occurs. Nikic keeps a Market Perform rating on Finish Line.
09/25/17
SUSQ
09/25/17
NO CHANGE
Target $12
SUSQ
Positive
Finish Line takeout thesis remains intact, says Susquehanna
Susquehanna analyst Sam Poser is telling investors to buy Finish Line shares as little has changed with his thesis following its Q2 results. The analyst noted fundamentals remain weak but he continues to believe Sports Direct will acquire the company and puts the odds at 75%. Poser has a $12 price target on Finish Line shares.
IONS Ionis Pharmaceuticals
$50.70

-1.91 (-3.63%)

09/29/17
WELS
09/29/17
NO CHANGE
WELS
Outperform
Ionis deaths in Spinraza patients related to disease, says Wells Fargo
Wells Fargo analyst Jim Birchenough noted Ionis Pharmaceuticals (IONS) shares have been weak today amid reports of deaths in patients treated with Spinraza for spinal muscular atrophy, but his review of the FAERS system data indicates that in each of the 12 deaths reported disease progression appears to be the cause of death. He said that, if anything, he would expect the disease-related deaths to accelerate approval of new born testing for early identification. Birchenough has an Outperform rating on Ionis shares.
09/29/17
BMOC
09/29/17
NO CHANGE
BMOC
Outperform
Ionis reaction to reports of death in database unwarranted, says BMO Capital
BMO Capital analyst Do Kim believes the pressure on Ionis shares after nine reported deaths of Spinraza patients were found using the FDA AERS database is unwarranted, noting that SMA Type 1 is usually fatal before one year. The analyst believes these deaths are not drug related and thinks the Q3 consensus Spinraza estimate is beatable. Kim keeps an Outperform rating on Ionis shares.
09/21/17
LEHM
09/21/17
NO CHANGE
Target $127
LEHM
Overweight
Alnylam price target raised to $127 from $105 at Barclays
Barclays analyst Gena Wang raised her price target for Alnylam Pharmaceuticals (ALNY) to $127 citing the company's positive topline data from the Apollo Phase study in TTR amyloidosis. The analyst increased patisiran's probability of success to 95% from 85% and reiterates an Overweight rating on the shares. Wang also decreased her price target on Equal Weight-rated Ionis Pharmaceuticals (IONS) to $52 from $55 saying Alnylam's data suggest strong competition for inotersen.
09/20/17
JEFF
09/20/17
NO CHANGE
Target $102
JEFF
Buy
Jefferies says Alnylam patisiran results a 'best-case scenario'
Jefferies analyst Maury Raycroft views Alnylam's (ALNY) topline results from the Apollo trial of patisiran as "highly positive" and a "best-case scenario" from a competitive perspective. The lack of any notable safety signal and benefit on secondary endpoints further distinguishes this "as a clear win" and should help the company's negotiations with payers, he tells investors. Patisiran appears to have a superior safety profile to Ionis' (IONS) inotersen, added Raycroft, who has a Buy rating and $102 price target on Alnylam shares.
SRPT Sarepta
$45.36

-1.79 (-3.80%)

09/27/17
LEER
09/27/17
NO CHANGE
LEER
Outperform
Sarepta doesn't see read through from PTC AdComm, says Leerink
After hosting Sarepta (SRPT) executives, Leerink analyst Joseph Schwartz noted management stated they do not anticipate any read through to Sarepta's exon skipping drugs from the advisory committee meeting to discuss PTC Therapeutics' (PTCT) ataluren as the therapies have different mechanisms and address different disease states. Additionally, the company said Exondys 51's U.S. launch has exceeded expectations, sales outside the U.S. are expected to be slower than U.S. sales, that they see a potential FDA filing for golodirsen in Q1 of 2018 and that they will update guidance in 2018. Schwartz keeps an Outperform rating on Sarepta shares.
09/29/17
WBLR
09/29/17
NO CHANGE
WBLR
Outperform
Sarepta should be bought on today's weakness, says William Blair
William Blair analyst Tim Lugo recommends using today's weakness in shares of Sarepta Therapeutics as a buying opportunity. The analyst believes the adverse events posted in the FDA's Adverse Event Reporting System are likely not related to Sarepta's Exondys 51.
09/29/17
NOMU
09/29/17
NO CHANGE
Target $84
NOMU
Buy
Sarepta should be bought on today's weakness, says Nomura Instinet
The FDA Adverse Events Reporting System Public Dashboard became available this morning and highlighted three patients treated with Sarepta Therapeutics' Exondys-51, Nomura Instinet analyst Christopher Marai tells investors in an intraday research note titled "Deaths Consistent with DMD, Not Drug Related." The deaths reported are not related to the drug and are consistent with outcomes in late-stage Duchenne muscular dystrophy, Marai tells investors in a research note after speaking with the company. He believes the deaths highlight the "extreme unmet need faced by patients with DMD and importance of early dosing." The analyst recommends accumulating shares of Sarepta on today's weakness. Exondys-51's safety profile to date suggest it remains a "very safe therapeutic," Marai adds. He keeps a Buy rating on Sarepta with an $84 price target. The stock in midday trading is down 4% to $45.16.
09/29/17
FBCO
09/29/17
NO CHANGE
FBCO
Outperform
Sarepta says three deaths reported not related to study drug, says Credit Suisse
Credit Suisse analyst Alethia Young said she spoke to Sarepta management after receiving questions about Exondys 51 after the FDA made its Adverse Events Reporting Database a public site. All 3 cases of deaths that were brought up by those searching the FAERS were older patients who were at the end of their life and not related to the study drug, Young said she was told. The analyst has an Outperform rating on Sarepta shares.
LPX Louisiana-Pacific
$27.08

-1.49 (-5.22%)

05/08/17
05/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Goldman Sachs analyst Mark Delaney downgraded Micron (MU) Technology to Neutral from Buy and lowered his price target for the shares to $30 from $32. With consensus estimates up 70% for the current fiscal year on better memory prices and margins, the major catalyst for shares has already played out, Delaney tells investors. 2. Bank of America Merrill Lynch analyst Steve Byrne downgraded LyondellBasell (LYB) two notches to Underperform from Buy and lowered its price target to $80 from $100, telling investors supply growth is set to impact margins. The analyst said polyethylene industry is over-earning and capacity has accelerated and will result in global polyethylene supply growth that is expected to exceed demand through 2018. 3. Goldman Sachs analyst Toshiya Hari removed Lam Research (LRCX) from the Conviction Buy List given recent outperformance. The analyst maintains a Buy rating and increased his price target to $160 from $153, citing strong industry fundamentals and market share gains, among other reasons. 4. Deutsche Bank analyst Jonathan Arnold downgraded Consolidated Edison (ED) to Sell saying the valuation is "stretched" at current share levels. The analyst sees 7% downside to his unchanged price target of $74. 5. DA Davidson analyst Steven Chercover downgraded Louisiana-Pacific (LPX) to Neutral citing valuation following the company's Q1 results, as he believes "much of the good news on commodities" is already priced into the shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/25/17
RBCM
09/25/17
NO CHANGE
RBCM
Louisiana-Pacific price target raised to $37 from $32 at RBC Capital
RBC Capital analyst Paul Quinn raised his price target on Louisiana-Pacific citing higher OSB prices in the wake of the recent hurricanes and the high margins of the company's siding business. He keeps an Outperform rating on the shares.
09/29/17
BMOC
09/29/17
DOWNGRADE
BMOC
Underperform
Louisiana-Pacific downgraded to Underperform from Market Perform at BMO Capital
09/29/17
BMOC
09/29/17
DOWNGRADE
BMOC
Underperform
Louisiana-Pacific downgraded at BMO Capital
As noted earlier, BMO Capital downgraded Louisiana-Pacific to Underperform from Market Perform. As reasons for the downgrade, analyst Ketan Mamtora cited valuation and upcoming OSB supply increases. The analyst believes that the supply increases set to occur over the next 6-9 months will pressure OSB prices. Target to $24 from $22.

TODAY'S FREE FLY STORIES

MSBI

Midland States

$33.03

-0.07 (-0.21%)

19:02
10/16/17
10/16
19:02
10/16/17
19:02
Hot Stocks
Midland States to acquire Alpine Bancorporation in roughly $181M deal »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

MYL

Mylan

$38.18

0.23 (0.61%)

, AGN

Allergan

$198.41

-7.11 (-3.46%)

18:46
10/16/17
10/16
18:46
10/16/17
18:46
Hot Stocks
Mylan CEO: 'Pleased' with court ruling on Allergan's Restasis patents »

Mylan (MYL) announced…

MYL

Mylan

$38.18

0.23 (0.61%)

AGN

Allergan

$198.41

-7.11 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

  • 03

    Dec

NFLX

Netflix

$202.68

3.19 (1.60%)

18:44
10/16/17
10/16
18:44
10/16/17
18:44
Hot Stocks
Netflix says seeing steady growth, great success for streaming »

Says still has bias…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

PCG

PG&E

$53.43

-4.29 (-7.43%)

18:42
10/16/17
10/16
18:42
10/16/17
18:42
Hot Stocks
PG&E sees restoring service to all electric customers in CA affected by fires »

PG&E said that more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 05

    Nov

  • 05

    Nov

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

18:29
10/16/17
10/16
18:29
10/16/17
18:29
Hot Stocks
CytRx granted listing extension pending results of stockholder vote »

CytRx 's request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

EADSY

Airbus

$22.75

-0.07 (-0.31%)

, BDRBF

Bombardier

$1.88

0.03 (1.62%)

18:27
10/16/17
10/16
18:27
10/16/17
18:27
Hot Stocks
Airbus and Bombardier announce C Series partnership »

Airbus (EADSY) and…

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BDRBF

Bombardier

$1.88

0.03 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

18:16
10/16/17
10/16
18:16
10/16/17
18:16
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

PG

Procter & Gamble

$93.14

0.1 (0.11%)

18:15
10/16/17
10/16
18:15
10/16/17
18:15
Hot Stocks
Trian: P&G board election results 'too close to call' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

18:14
10/16/17
10/16
18:14
10/16/17
18:14
Periodicals
NJ leaders offer up to $7B in tax incentives to lure Amazon to Newark, WSJ says »

New Jersey Governor Chris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

18:09
10/16/17
10/16
18:09
10/16/17
18:09
Periodicals
Bombardier in talks with Airbus over CSeries jet unit JV, WSJ reports »

Bombardier (BDRBF) is in…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

ADOM

Adomani

$6.50

-0.36 (-5.25%)

17:21
10/16/17
10/16
17:21
10/16/17
17:21
Syndicate
Breaking Syndicate news story on Adomani »

Adomani files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

17:20
10/16/17
10/16
17:20
10/16/17
17:20
Hot Stocks
Spirit Airlines raises Q3 total RASM view to (6.5%) from (8.5%)-(7%) »

Sees Q3 ASMs up 18%. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$4.38

-0.08 (-1.79%)

17:16
10/16/17
10/16
17:16
10/16/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Resonant »

Longboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.